ConcertAI is a leading provider of real-world evidence (RWE) and artificial intelligence (AI) technology solutions specifically tailored for oncology and healthcare. The company has developed a comprehensive suite of AI-powered products and services that leverage a vast repository of multi-modal oncology data, which includes genomic, transcriptomic, clinical, and social determinants of health data. This extensive data set, representing over 8 million patients, enables ConcertAI to offer advanced analytics and insights that support clinical development, trial design, and patient care. Their CARA AI platform is central to these efforts, facilitating the integration of AI models for clinical trial patient matching, protocol automation, and real-time analytics.

In collaboration with industry leaders such as NVIDIA and Caris Life Sciences, ConcertAI is advancing precision oncology research and therapeutic development. The partnership with NVIDIA focuses on enhancing the scalability and performance of AI models through advanced computing capabilities, while the collaboration with Caris aims to create a prospectively matched clinico-genomic research platform. This platform will combine molecular profiling with clinical data to generate novel insights for precision medicine. Overall, ConcertAI's commitment to harnessing AI and RWE is driving innovation in healthcare, ultimately aiming to improve patient outcomes and accelerate the development of new therapies.

United States

Their mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, healthcare providers, and medical societies.

ConcertAI

Company Details